Relay Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€7.17M - Cost of goods sold
€7.08M - Gross profit
€94.38K - SG&A expenses
€59.22M - R&D expenses
€242.30M - EBITDA
-€290.18M - D&A
€2.32M - EBIT
-€294.35M - Interest expenses
€0.00 - EBT
-€267.31M - Tax expenses
€0.00 - Net income
-€267.31M
Cash flow statement
- Net deferred tax
€0.00 - Non-cash items
€4.87M - Changes in working capital
-€18.26M - Operating cash flow
-€224.30M - Capex
€546.55K - Other investing cash flow
€0.00 - Net investing cash flow
€17.54M - Total cash dividends paid
€0.00 - Issuance of common stock
-€16.71M - Debt repayment
€0.00 - Other financing cash flow
€1.31M - Net financing cash flow
€189.05M - Foreign exchange effects
€0.00 - Net change in cash
-€17.70M - Cash at end of period
€99.70M - Free cash flow
-€223.75M
Balance sheet
- Cash and cash equivalents
€97.76M - Cash and short-term investments
€97.76M - Total receivables
€0.00 - Inventory
€0.00 - Other current assets
€486.02M - Total current assets
€583.78M - Property, plant & equipment
€39.63M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€1.94M - Other non-current assets
€0.00 - Total non-current assets
€41.57M - Total assets
€625.35M - Accounts payable
€4.44M - Short-term debt
€3.02M - Other current liabilities
€20.44M - Total current liabilities
€27.91M - Long-term debt
€26.30M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€0.00 - Total non-current liabilities
€26.30M - Total liabilities
€54.21M - Common stock
€144.14K - Retained earnings
-€1.62B - Other equity
-€139.85K - Total equity
€571.14M - Total liabilities and shareholders' equity
€625.35M
Company information
- Market capitalization
€482.57M - Employees
259 - Enterprise Value
€526.24M
Company ratios
- Gross margin
-
1.3% Much better than peer group: -20,695.1% - EBITDA margin
-
-4,047.4% Much better than peer group: -28,895.2% - EBIT margin
-
-4,105.6% Much better than peer group: -29,093.7% - EBT margin
-
-3,728.4% Much better than peer group: -29,168.2% - Net margin
-
-3,728.4% Much better than peer group: -29,123.1% - ROE
-
-46.8% Much better than peer group: -279.4% - ROA
-
-42.7% Worse than peer group: -35.3% - Asset turnover
-
1.1% Worse than peer group: 8.7% - FCF margin
-
-3,136.2% Much better than peer group: -26,028.8% - FCF yield
-46.6% - Efficiency ratio
4,147.4% - Net sales per employee
-
€27.68K - Net income per employee
-
-€1.03M